
    
      The secondary objective of this study will be: (i) evaluation of the improvement of side
      effects due to HLA-B27 associated uveitis such as intraocular pressure (IOP), cystoid macular
      edema, keratophaty and synechia (ii) evaluation of the improvement in uveitis-related
      symptoms: BCVA and symptoms measured by VAS, like ocular pain, photophobia, floaters and
      blurred vision; (iii) evaluation of cell damage and inflammation reduction in patients with
      HLA-B27 associated uveitis; (iv) evaluation of the patients' attitude towards the study
      treatment and also the evaluation of the safety profile of the study product.
    
  